Shenzhen-based biotechnology company ImmVira has announced the successful completion of Phase I clinical studies in the United States for its intravenous oncolytic virus product, MVR-T3011 IV. The trial, which focuses on late stage patients with various tumor types, yielded “exceptional” safety results and demonstrated initial efficacy for certain indicationsThe study also generated pharmacokinetic/pharmacodynamic (PK/PD) and immune response data, which will be instrumental in guiding the Phase II study.
MVR-T3011 IV: A Novel Oncolytic Virus with Immunotherapeutic Potential
ImmVira’s MVR-T3011 IV is an oncolytic herpes simplex virus (oHSV) that incorporates immunotherapeutic genes encoding IL-12 and a PD-1 antibody. This design allows the virus to be directed into tumors, overcoming the issue of viral dilution that other oncolytic viruses face. Data from 12 evaluable participants showed significant tumor reduction in patients with endometrial, appendiceal, and gallbladder cancer. The US data will also be leveraged to support ongoing trials in China for this therapeutic candidate.- Flcube.com
